SMTL ID : 8xv3.1 (1 other biounit)

Crystal structure of the catalytic domain of human PDE10A complexed with (2-((4-(5-(2-methylpyridin-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)methyl)quinolin-4-yl)(2,6-diazaspiro[3.3]heptan-2-yl)methanone

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.30 Å

Oligo State

monomer

Ligands

1 x 01: 2,6-diazaspiro[3.3]heptan-2-yl-[2-[[4-[5-(2-methylpyridin-4-yl)-3-(trifluoromethyl)pyrazol-1-yl]phenoxy]methyl]quinolin-4-yl]methanone

01.1: 18 residues within 4Å: Chain A: Y.76, L.187, L.227, S.229, V.230, T.240, I.244, Y.245, F.248, P.264, M.265, K.270, E.273, V.274, Q.276, G.277, Q.278, F.281 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:L.187, A:L.227, A:I.244, A:F.248, A:F.248, A:E.273, A:V.274, A:F.281 Hydrogen bonds: A:Q.278 pi-Stacking: A:F.281 Halogen bonds: A:L.227

1 x ZN: ZINC ION(Non-covalent)

ZN.2: 5 residues within 4Å: Chain A: H.81, H.115, D.116, D.226 Ligands: MG.3 5 PLIP interactions: 4 interactions with chain A, 1 Ligand-Water interactions Metal complexes: A:H.81, A:H.115, A:D.116, A:D.226, H2O.3

1 x MG: MAGNESIUM ION(Non-covalent)

MG.3: 6 residues within 4Å: Chain A: H.115, D.116, E.144, H.147, T.185 Ligands: ZN.2 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:D.116, H2O.1, H2O.2, H2O.3, H2O.3

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Zhang, F.C. et al., Structure-based design and optimization of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors with improved metabolic stability to attenuate isoprenaline-induced cardiac hypertrophy. To Be Published

Release Date

2025-01-15

Peptides

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A

Related Entries With Identical Sequence